Rivaroxaban for the treatment and prevention of thromboembolic disease

Journal of Pharmacy and Pharmacology

Volumn 67, Issue 8, 2015, Pages 1119-1132

  Antoniou, Sotiris ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

anticoagulant; pharmacodynamics; pharmacokinetics; rivaroxaban; thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10A INHIBITOR; CARBAMAZEPINE; CLARITHROMYCIN; CLOPIDOGREL; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; DABIGATRAN ETEXILATE; DRONEDARONE; ERYTHROMYCIN; FLUCONAZOLE; FONDAPARINUX; HEPARIN; HEPARIN DERIVATIVE; HYPERICUM PERFORATUM EXTRACT; LOW MOLECULAR WEIGHT HEPARIN; MULTIDRUG RESISTANCE PROTEIN; NAPROXEN; PHENOBARBITAL; PHENYTOIN; PLACEBO; PRASUGREL; PROTEIN INHIBITOR; RIFAMPICIN; RIVAROXABAN; TICLOPIDINE; UNINDEXED DRUG; WARFARIN; CYTOCHROME P450 3A;

AGE; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BLEEDING; BODY WEIGHT; CEREBROVASCULAR ACCIDENT; DEEP VEIN THROMBOSIS; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG INDICATION; DRUG METABOLISM; DRUG MONITORING; DRUG SUBSTITUTION; DRUG USE; FIRST PASS EFFECT; FOOD DRUG INTERACTION; GENDER; HEALTH CARE PERSONNEL; HUMAN; INFORMATION RETRIEVAL; LOADING DRUG DOSE; LUNG EMBOLISM; MAXIMUM PLASMA CONCENTRATION; MEDLINE; NONHUMAN; PATIENT CARE; PHARMACODYNAMICS; PRACTICE GUIDELINE; RISK BENEFIT ANALYSIS; SINGLE DRUG DOSE; THROMBOEMBOLISM; THROMBOSIS; VENOUS THROMBOEMBOLISM; ATRIAL FIBRILLATION; CLINICAL TRIAL (TOPIC); DOSE RESPONSE; DRUG INTERACTION; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PULMONARY EMBOLISM; VENOUS THROMBOSIS;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; CLINICAL TRIALS AS TOPIC; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FACTOR XA INHIBITORS; HUMANS; P-GLYCOPROTEIN; PULMONARY EMBOLISM; RIVAROXABAN; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 84936995498     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/jphp.12387     Document Type: Article

References (70)

1. Ageno W, et al. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141: e44S-e88S.
2. Eikelboom JW, Weitz JI,. New anticoagulants. Circulation 2010; 121: 1523-1532.
3. Weitz JI, Bates SM,. New anticoagulants. J Thromb Haemost 2005; 3: 1843-1853.
4. Garcia DA, et al. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141: e24S-e43S.
5. Pudusseri A, et al. A new paradigm shift in antithrombotic therapy. Front Pharmacol 2013; 4: 133.
6. Bayer Pharma AG,. Xarelto® (rivaroxaban) Summary of Product Characteristics [Online]. 2015. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000944/WC500057108.pdf (accessed 14 May 2015).
7. Perzborn E, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct Factor Xa inhibitor. J Thromb Haemost 2005; 3: 514-521.
8. Samama MM,. The mechanism of action of rivaroxaban-an oral, direct Factor Xa inhibitor-compared with other anticoagulants. Thromb Res 2011; 127: 497-504.
9. Kubitza D, et al. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct Factor Xa inhibitor. Clin Pharmacol Ther 2005; 78: 412-421.
10. Kubitza D, et al. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005; 61: 873-880.
11. Stampfuss J, et al. The effect of food on the absorption and pharmacokinetics of rivaroxaban. Int J Clin Pharmacol Ther 2013; 51: 549-561.
12. Mueck W, et al. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet 2014; 53: 1-16.
13. Weinz C, et al. Metabolism and excretion of rivaroxaban, an oral, direct Factor Xa inhibitor, in rats, dogs and humans. Drug Metab Dispos 2009; 37: 1056-1064.
14. Lang D, et al. In vitro metabolism of rivaroxaban-an oral, direct Factor Xa inhibitor-in liver microsomes and hepatocytes of rat, dog and man. Drug Metab Dispos 2009; 37: 1046-1055.
15. Kubitza D, et al. Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin 2008; 24: 2757-2765.
16. Graff J, et al. Effects of the oral, direct Factor Xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity. J Clin Pharmacol 2007; 47: 1398-1407.
17. Kubitza D, et al. The influence of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct Factor Xa inhibitor. J Clin Pharmacol 2013; 53: 249-255.
18. Kubitza D, et al. Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J Clin Pharmacol 2007; 47: 218-226.
19. Kubitza D, et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol 2010; 70: 703-712.
20. Kubitza D, et al. Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban-an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol 2013; 76: 89-98.
21. Mueck W, et al. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol 2013; 76: 455-466.
22. Kubitza D, et al. Rivaroxaban (BAY 59-7939)-an oral, direct Factor Xa inhibitor-has no clinically relevant interaction with naproxen. Br J Clin Pharmacol 2007; 63: 469-476.
23. Kubitza D, et al. Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban-an oral, direct Factor Xa inhibitor-are not affected by aspirin. J Clin Pharmacol 2006; 46: 981-990.
24. Kubitza D, et al. Effect of co-administration of rivaroxaban and clopidogrel on bleeding time, pharmacodynamics and pharmacokinetics: a phase I study. Pharmaceuticals (Basel) 2012; 5: 279-296.
25. Kubitza D, et al. The discovery of rivaroxaban: translating preclinical assessments into clinical practice. Front Pharmacol 2013; 4: 145.
26. Haas S, et al. Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk. Vasc Health Risk Manag 2014; 10: 101-114.
27. Agnelli G, et al. Treatment of proximal deep-vein thrombosis with the oral direct Factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients with Acute Symptomatic Deep-Vein Thrombosis) study. Circulation 2007; 116: 180-187.
28. Buller HR, et al. A dose-ranging study evaluating once-daily oral administration of the Factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood 2008; 112: 2242-2247.
29. Buller H,. Once-weekly subcutaneous idraparinux (anti Xa) versus oral vitamin K antagonist therapy for the prevention of thromboembolic events in patients with atrial fibrillation-(Amadeus). J Thromb Haemost 2007; 5 Suppl 2. Abstract O-W-054.
30. Fiessinger JN, et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA 2005; 293: 681-689.
31. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-2510.
32. The EINSTEIN-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287-1297.
33. Kearon C, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141: e419S-e494S.
34. You JJ, et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141: e531S-e575S.
35. Patel MR, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891.
36. Eriksson BI, et al. Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2006; 4: 121-128.
37. Eriksson BI, et al. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation 2006; 114: 2374-2381.
38. Eriksson BI, et al. Dose-escalation study of rivaroxaban (BAY 59-7939)-an oral, direct Factor Xa inhibitor-for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Res 2007; 120: 685-693.
39. Turpie AGG, et al. BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost 2005; 3: 2479-2486.
40. Eriksson BI, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358: 2765-2775.
41. Kakkar AK, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008; 372: 31-39.
42. Lassen MR, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358: 2776-2786.
43. Turpie AGG, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009; 373: 1673-1680.
44. Mega JL, et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 2009; 374: 29-38.
45. Mega JL, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366: 9-19.
46. Torbicki A, et al. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 2008; 29: 2276-2315.
47. Prins MH, et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J 2013; 11: 21.
48. Schirmer SH, et al. Novel anticoagulants for stroke prevention in atrial fibrillation: current clinical evidence and future developments. J Am Coll Cardiol 2010; 56: 2067-2076.
49. Falck-Ytter Y, et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141: e278S-e325S.
50. Friedman RJ, et al. Physician compliance with guidelines for deep-vein thrombosis prevention in total hip and knee arthroplasty. Curr Med Res Opin 2008; 24: 87-97.
51. Turpie AGG, et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost 2011; 105: 444-453.
52. Wiviott SD, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
53. Wallentin L, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057.
54. Zhao HJ, et al. Triple therapy' rather than 'triple threat': a meta-analysis of the two antithrombotic regimens after stent implantation in patients receiving long-term oral anticoagulant treatment. Chest 2011; 139: 260-270.
55. Andreotti F, et al. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. Eur Heart J 2006; 27: 519-526.
56. Imberti D, Benedetti R,. Practical management of rivaroxaban for the treatment of venous thromboembolism. Clin Appl Thromb Hemost 2015; 21: 309-318.
57. Turpie AGG, et al. Management consensus guidance for the use of rivaroxaban-an oral, direct Factor Xa inhibitor. Thromb Haemost 2012; 108: 876-886.
58. Bauer KA,. Reversal of antithrombotic agents. Am J Hematol 2012; 87 (Suppl. 1): S119-S126.
59. Samama MM, et al. Evaluation of the anti-Factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost 2012; 107: 379-387.
60. Lindhoff-Last E, et al. Laboratory testing of rivaroxaban in routine clinical practice: when, how, and which assays. Ann Med 2013; 45: 423-429.
61. National Institute for Health and Clinical Excellence. Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism. Technology appraisal 261 [Online]. 2012. Available from: http://www.nice.org.uk/ta261 (accessed 14 May 2015).
62. National Institute for Health and Care Excellence. Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism; NICE technology appraisal guidance 287 [Online]. 2013. Available from: http://www.nice.org.uk/guidance/TA287 (accessed 14 May 2015).
63. Mahmoudi M, Sobieraj DM,. The cost-effectiveness of oral direct Factor Xa inhibitors compared with low-molecular-weight heparin for the prevention of venous thromboembolism prophylaxis in total hip or knee replacement surgery. Pharmacotherapy 2013; 33: 1333-1340.
64. Duran A, et al. Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a US payer's perspective. Pharmacoeconomics 2012; 30: 87-101.
65. Ryttberg L, et al. Cost-effectiveness of rivaroxaban versus heparins for prevention of venous thromboembolism after total hip or knee surgery in Sweden. Expert Rev Pharmacoecon Outcomes Res 2011; 11: 601-615.
66. National Institute for Health and Clinical Excellence. Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation. Technology appraisal TA256 [Online]. 2012. Available from: http://www.nice.org.uk/ta256 (accessed 14 May 2015).
67. Kansal AR, et al. Cost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillation. Best Pract Res Clin Haematol 2013; 26: 225-237.
68. Lee S, et al. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation. Am J Cardiol 2012; 110: 845-851.
69. National Institute for Health and Clinical Excellence. NICE technology appraisal guidance 170: rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults [Online]. 2009. Available from: http://www.nice.org.uk/guidance/ta170 (accessed 14 May 2015).
70. National Institute for Health and Clinical Excellence. Costing statement: rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults [Online]. 2010. Available from: http://www.nice.org.uk/guidance/ta170/costing (accessed 14 May 2015).